Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotechnology sector, focusing on developing treatments for cancer and rare diseases. Under the leadership of CEO Dr. Vuong Trieu, the company is leveraging artificial intelligence and nanomedicine to innovate in biotechnology.
The company's intellectual property portfolio includes approximately 500 patent applications and 75 granted patents. Oncotelic is specifically targeting difficult-to-treat cancers such as glioblastoma and pancreatic cancer, along with rare pediatric disorders, addressing significant unmet medical needs in these areas.
Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotech industry, focusing on developing treatments for aggressive cancers and pediatric rare diseases. Under CEO Dr. Vuong Trieu's leadership, the company is leveraging artificial intelligence, nanomedicine, and novel clinical models to advance its therapeutic pipeline.
The company's intellectual property portfolio includes over 500 patent applications and 75 issued patents. Oncotelic is specifically targeting difficult-to-treat conditions such as glioblastoma and pancreatic cancer, aiming to address significant unmet medical needs in these areas through RNA-based and immunotherapy approaches.
Oncotelic Therapeutics (OTCQB: OTLC) has provided a comprehensive update on its clinical and regulatory progress over the past two years. The company's pipeline features multiple late-stage drug candidates targeting oncology and rare diseases.
Key programs include OT-101 in Phase 3 for pancreatic cancer, OXi4503 advancing to Phase 3 for AML/MDS, CA4P/Fosbretabulin for oncology, AL-101 in Phase 2 for Parkinson's and sexual dysfunctions, and AL-102 for Alzheimer's disease. The company is also developing pediatric rare disease programs and a nanomedicine pipeline utilizing the 505(b)(2) pathway for expedited approval.
Oncotelic Therapeutics (OTCQB: OTLC) highlighted the contributions of Chairman and CEO Dr. Vuong Trieu and provided an update on its clinical pipeline. Dr. Trieu, a renowned industry pioneer, has an extensive portfolio of over 500 filed patents and 75 issued patents covering various therapeutic areas.
His notable achievements include co-inventing Abraxane® (acquired for $2.9 billion) and developing Cynviloq™ (sold for $1.3 billion). The company's pipeline includes six key programs: OT-101 (Phase 3 for pancreatic cancer), OXi4503 (Phase 2 in AML/MDS), CA4P/Fosbretabulin, AL-101 (Phase 2 for Parkinson's), AL-102 (discovery stage), and pediatric rare disease programs.
Oncotelic Therapeutics (OTCQB: OTLC) showcased its robust pipeline and highlighted the intellectual property contributions of CEO Dr. Vuong Trieu. Dr. Trieu's portfolio includes over 500 filed patents and 75 issued patents, with notable achievements including co-inventing Abraxane® (acquired for $2.9 billion) and developing Cynviloq™ (sold for $1.3 billion).
The company's pipeline includes multiple clinical-stage assets: OT-101 (Phase 3 for pancreatic cancer), OXi4503 (Phase 2 in AML/MDS), CA4P/Fosbretabulin (late-stage oncology), AL-101 (Phase 2 for Parkinson's), AL-102 (discovery stage for Alzheimer's), and pediatric rare disease programs targeting orphan indications.
Oncotelic Therapeutics (OTCQB: OTLC) has highlighted a new peer-reviewed publication demonstrating the link between TGFB2 expression and survival rates in younger pancreatic cancer patients. The study revealed that high TGFB2 expression significantly reduced overall survival in patients under 65 years, with median survival of 17.9 months versus 66.9 months for those with low expression.
The research supports further evaluation of the company's investigational antisense drug OT-101 (trabedersen) as a TGFB2-targeted treatment for pancreatic ductal adenocarcinoma (PDAC). Clinical data from the OT-101 P001 PDAC study showed promising results, with a median overall survival of 12.7 months in a treated subset with low IL-6.
Oncotelic Therapeutics (OTCQB: OTLC) has published a groundbreaking study in the International Journal of Molecular Sciences identifying TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). The research, conducted in collaboration with Sapu Biosciences, revealed that patients with high TGFB2 methylation and low immune markers showed a significant median overall survival exceeding 50 months.
The findings support the development of OT-101, Oncotelic's investigational antisense oligonucleotide targeting TGFB2 mRNA. The study utilized PDAOAI, the company's AI-powered chatbot platform, for literature mining and analysis, demonstrating the integration of artificial intelligence in scientific research.
Oncotelic Therapeutics (OTCQB:OTLC) announced that CEO Dr. Vuong Trieu will deliver a keynote presentation on their innovative Deciparticles™ platform at the IDDST-Europe Conference in Stockholm, June 18-20, 2025.
Deciparticles represent a breakthrough in drug delivery technology as sub-20 nm nanoparticles designed to overcome challenges in delivering insoluble drugs to solid tumors. The platform has demonstrated success in formulating over 90% of tested water-insoluble drugs, including taxanes.
Key highlights include:
- Enhanced tumor penetration and superior antitumor efficacy compared to conventional formulations
- Integration of biomarker-driven strategies using DNA methylation signatures
- Lead candidate Sapu-001 showing promising preclinical results with higher maximum-tolerated dose and reduced toxicity
The presentation is scheduled for June 19, 2025, at 10:30 CET, with Phase 1 clinical trials for Sapu-001 anticipated later in 2025.
Oncotelic Therapeutics (OTCQB:OTLC) has reported its FY 2024 financial results, marking a transformational year with significant developments. The company's joint venture, GPM Biotechnology , achieved GMP certification for its San Diego facility and obtained a Drug Manufacturing License. The facility is developing 6 nanoparticle compounds, including OT-101, with two compounds approaching IND filing stage.
The company has partnered with Shanghai Medicilon to utilize their rapid IND platform for up to 20 new filings. OT-101 is currently in Phase 3 trials for pancreatic cancer and has completed a phase 1 combination trial with IL-2. The company has also launched PDAOAI, an AI platform specifically designed for pharmaceutical regulatory processes.
Financially, OTLC reported a reduced net loss of $4.52M in FY 2024, compared to $7.90M in FY 2023. The improvement was primarily due to lower goodwill impairment ($2.9M decrease) and reduced general administrative expenses. The company recorded no service revenue in 2024, compared to $70,000 in 2023.
Oncotelic Therapeutics (OTCQB:OTLC) has published groundbreaking research on glioblastoma (GBM) treatment, revealing that high TGFB2 gene methylation correlates with improved overall survival in patients, surpassing the predictive value of MGMT and TGFB1 methylation.
The study identified several genes and pathways linked to TGFB2 methylation that improve survival outcomes, including T-cell activation, antigen processing, and Toll-like receptor pathways. The research also found that MALT1 mRNA negatively impacted survival rates, suggesting a potential target for therapy.
To facilitate research collaboration, Oncotelic has launched its proprietary PDAOAI communication platform, allowing researchers to interact with the paper and referenced articles through a single interface. This marks the company's first publication utilizing their proprietary AI technology.